Clinical Trial Update: CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating CCI-779 (temsirolimus) in adults with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic sy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelogenous Leukemia

Drugs mentioned

• CCI-779 (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 2 | Status: COMPLETED